Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

A Proteomic Review of Factors Related to Neurodegenerative Diseases

Tom Robbie

The COVID-19 pandemic has killed millions and is a major public health burden worldwide. Previous studies have shown that a large number of his COVID-19 patients and survivors developed neurological symptoms and may be at increased risk for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). I know there is. Our aim is to use bioinformatic analyzes to uncover potential mechanisms that may explain the neurological symptoms and brain degeneration seen in COVID-19 patients, and by intervening early, The aim was to investigate common pathways between COVID-19, AD, and PD. In this study, we used the frontal cortex gene expression dataset to detect common differentially expressed genes (DEGs) in COVID-19, AD, and PD. A total of 52 common DEGs were then probed using functional annotation, protein-protein interaction (PPI) construction, drug candidate identification and regulatory network analysis. We found that synaptic vesicle cycle engagement and synaptic downregulation are common to these three diseases, suggesting that synaptic dysfunction may contribute to the development and progression of COVID-19-induced neurodegenerative disease. Five hub genes and one key module were obtained from the PPI network. Additionally, 5 drugs and 42 transcription factors (TFs) were also identified in the dataset. In summary, the results of our study provide new insights and guidance for follow-up studies on the relationship between COVID-19 and neurodegenerative diseases. The hub genes and potential drugs we identified may offer promising therapeutic strategies to prevent COVID-19 patients from developing these diseases.